Recursion Pharmaceuticals

Recursion Pharmaceuticals Net Change in Cash

The Net Change in Cash of Recursion Pharmaceuticals (RXRX) as of Oct 27, 2026 is 150.90 M USD. In the previous year, Net Change in Cash was 201.60 M USD — a change of -25.15% (lower).

Net Change in Cash

150.90 MUSD

YoY

-25.15%

Last updated:

Net Change in Cash of Recursion Pharmaceuticals is 2025 150.90 M USD. Net Change in Cash of Recursion Pharmaceuticals was 2024 201.60 M USD. It decreases by -25.15% lower compared to the previous year.

The Recursion Pharmaceuticals Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2019
59.46 M USD
Jan 1, 2020
192.00 M USD
Jan 1, 2021
28.18 M USD
Jan 1, 2022
263.76 M USD
Jan 1, 2023
-157.69 M USD
Jan 1, 2024
201.60 M USD
Jan 1, 2025
150.90 M USD
The Recursion Pharmaceuticals Net Change in Cash history
YEARNet Change in CashYoY
150.90 MUSD-25.15%
201.60 MUSD-227.85%
-157.69 MUSD-159.78%
263.76 MUSD+835.93%
28.18 MUSD-85.32%
192.00 MUSD+222.91%
59.46 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Net Change in Cash of Recursion Pharmaceuticals is 150.90 M USD in 2025.

Net Change in Cash of Recursion Pharmaceuticals changed from 201.60 M USD to 150.90 M USD, representing a -25.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Recursion Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals